Nadroparin calcium
Nadroparin calcium is an oligosaccharide pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | 1 | 4 | 1 | 1 | 6 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 4 | 1 | 5 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | 1 | 1 | 2 | — | 3 |
| Thrombosis | D013927 | — | — | — | 1 | 1 | 2 | ||
| Thromboembolism | D013923 | HP_0001907 | — | — | — | 2 | — | 2 | |
| Ischemic stroke | D000083242 | — | — | — | 1 | — | 1 | ||
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 1 | — | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | 1 | — | 1 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | 1 | — | 1 | |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal neoplasms | D004938 | C15 | — | — | — | — | 1 | 1 | |
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
| Artificial respiration | D012121 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NADROPARIN CALCIUM |
| INN | nadroparin calcium |
| Description | Nadroparin (trade names Fraxiparin[e], Fraxodi, among others) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo.
|
| Classification | Oligosaccharide |
| Drug class | heparin derivatives and low molecular weight (or depolymerized) heparins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 9005-49-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109204 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08813 |
| UNII ID | LIA7Z4002P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 277 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
142 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more